Bioimpedance in monitoring of effects of selective serotonin reuptake inhibitor treatment by Alexeev, Vasiliy Grigorievich & Kuznecova, Ludmila Vasilievna
© 2011 Alexeev and Kuznecova, publisher and licensee Dove Medical Press Ltd.   This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Psychology Research and Behavior Management 2011:4 81–86
Psychology Research and Behavior Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
81
ORIGINAL  RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/PRBM.S22925
Bioimpedance in monitoring of effects of selective 
serotonin reuptake inhibitor treatment
Vasiliy Grigorievich Alexeev
Ludmila Vasilievna 
Kuznecova
Department of Physiology, SP Botkin 
Moscow City Clinical Hospital, 
Moscow, Russia
Correspondence:   VG Alexeev 
SP Botkin Clinic and Hospital,  
2nd Botkinsky Proezd,  
125284 Moscow, Russia 
Tel +749 5945 0045 
Fax +749 5945 0045 
Email info@botkinmoscow.ru
Background: Bioimpedance has been shown to be a safe technique when used in a number 
of biomedical applications. In this study, we used the Electro Interstitial Scan (EIS) to perform 
bioimpedance measurements to follow up the efficacy of selective serotonin reuptake inhibitor 
(SSRI) treatment in subjects diagnosed to have major depressive disorder.
Methods: We recruited 59 subjects (38 women, 21 men) aged 17–76 (mean 47) years diag-
nosed with major depressive disorder by psychiatric assessment at the Botkin Hospital accord-
ing to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). 
Baseline Clinical Global Impression scores and EIS (electrical conductivity and dispersion α 
parameter) measurements were done before starting SSRI therapy. Treatment follow-up was 
undertaken using EIS bioimpedance measurements and by treatment response based on the 
Hamilton Depression Scale and Clinical Global Impression, every 15 days for 60 days. At day 45, 
we classified the patients into two groups, ie, Group 1, including treatment responders, and 
Group 2, including nonresponders. At day 60, patients were classified into two further groups, 
ie, Group 3, comprising treatment responders, and Group 4, comprising nonresponders.
Results: Comparing Group 1 and Group 2, electrical conductivity measurement of the path-
way between the two forehead electrodes had a specificity of 72% and a sensitivity of 85.3% 
(P , 0.0001), with a cutoff .4.32. Comparing Group 3 and Group 4, electrical conductivity 
measurements in the same pathway had a specificity of 47.6% and a sensitivity of 76.3% 
(P , 0.16), with a cutoff .5.92. Comparing Group 1 and Group 2, the electrical dispersion α 
parameter of the pathway between the two disposable forehead electrodes had a specificity of 
80% and a sensitivity of 85.2% (P , 0.0001) with a cutoff .0.678. Comparing Group 3 and 
Group 4, the electrical dispersion α parameter of the same pathway had a specificity of 100%, 
a sensitivity of 89.5% (P , 0.0001), and a cutoff .0.692.
Conclusion: Electrical conductivity measurement of the forehead pathway using EIS has a high 
specificity and sensitivity at day 45 when comparing treatment responders and nonresponders, 
but decreases at day 60. The EIS electrical dispersion α parameter of the forehead pathway has 
a high specificity and sensitivity at day 45 when comparing treatment responders and nonre-
sponders, and increases at day 60. The EIS system may be a noninvasive, easily administered, 
low-cost technique that could be used as an adjunct to DSM-IV and Clinical Global Impression 
scores for monitoring of efficacy of treatment in patients with major depressive disorder.
Keywords: major depressive disorder, selective serotonin reuptake inhibitors, Electro Interstitial 
Scan, electrical conductivity, dispersion α parameter
Introduction
Depression is a common illness with a high degree of morbidity and mortality.1 It is 
a serious disorder that interferes with physical and mental functioning to a greater Psychology Research and Behavior Management 2011:4 submit your manuscript | www.dovepress.com
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extent than a number of other common chronic conditions, 
including hypertension, arthritis, and diabetes.1 Major depres-
sion significantly affects the quality of life and productivity 
of the patient. Early recognition and treatment are essential 
to minimize the personal and societal cost associated with 
depression.2 In spite of the serious consequences associ-
ated with untreated depression, most studies report that it 
remains largely underdiagnosed and inadequately treated.2 
Nevertheless, it is encouraging to note that if treated early 
and appropriately with an antidepressant, approximately 
60%–70% of patients respond to the initial course of therapy.3 
People respond differently to a variety of treatments, and 
only Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV)4 and Clinical Global Impression 
(CGI) scores5 are considered to be reliable methods for 
assessing treatment response. The likelihood of response to 
a given medication is well known, but psychiatrists are not 
able to predict if therapy will be effective in an individual 
patient. In clinical practice, psychiatrists use the method of 
trial and error.6
Bioimpedance has been shown to be a safe technique when 
used in a number of biomedical applications, including for 
estimation of body composition,7 impedance cardiography,8 
quantification of brain edema in neurosurgery,9 and for detec-
tion of differences between normal, abnormal, and malignant 
prostate tissue.10 In this study, we used the Electro Interstitial 
Scan (EIS) to perform bioimpedance measurements as fol-
low-up of the effect of selective serotonin reuptake inhibitor 
(SSRI) treatment in patients diagnosed with major depressive 
disorder. This follow-up was performed from the conduc-
tivity and dispersion values of the pathway between two 
disposable electrodes placed on the forehead and compared 
with the results of assessment using DSM-IV questionnaire 
and the CGI scale.
Methods and materials
This study was approved by the ethics committee at   Botkin 
Hospital, and adhered to the ethical principles of the 
Declaration of Helsinki. Each patient signed an informed 
consent form, and confidentiality was maintained for all 
participants.
Subjects
Fifty-nine subjects (38 women, 21 men) of mean age 47 
(range 17–76) years were recruited from the Psychiatric 
Department of Botkin Hospital. Patients were excluded if 
they had a neurological disorder precluding ability to sign 
a consent form, if in the opinion of the investigator they 
were clinically unsuitable candidates for the trial, and/or had 
any contraindications to use of the EIS system. Use of the EIS 
is contraindicated in the presence of an external defibrillator, 
skin lesions likely to come into contact with the electrodes, 
excessive perspiration, a cardiac pacemaker, electronic life 
support, any implanted electronic device, inability to remain 
still for three minutes, metallic pins or prostheses in the digits 
or joints, pregnancy from the third trimester onwards, and 
absence of a limb.
All 59 patients had a clinical diagnosis of major depressive 
disorder as scored on the Hamilton Depression11 (Ham-D) 
and CGI scales. Once diagnosed, the patients were sent to the 
Department of Physiology at Botkin Hospital before starting 
antidepressant treatment, and an examination was performed 
using the EIS. The patients were then started on an SSRI 
(fluoxetine 20 mg/day), and follow-up was undertaken using 
both EIS bioimpedance measurements and Ham-D and/or CGI 
scores at 15-day intervals for 60 days. Treatment response 
was defined as a score of 1 or 2 on the CGI improvement 
scale and/or a decrease of at least 50% in Ham-D score. At 
day 45, patients were classified into two groups, ie, Group 1 
(responders) and Group 2 (nonresponders). At day 60, patients 
were again classified into two groups, ie, Group 3 (responders) 
and Group 4 (nonresponders).
Materials
The EIS system is a programmable electromedical system 
comprising a USB plug and hardware including an interface 
box, disposable electrodes, reusable plates, and reusable 
cables, with software installed on a computer. The system uses 
bioimpedance in bipolar mode with direct current (1.28 V), 
and measures the electrical conductivity and dispersion α 
parameter in 11 pathways of the body using six electrodes 
placed symmetrically on the palms of the hands, soles of the 
feet, and on the forehead. Each pathway is recorded twice from 
anode to cathode and then from cathode to anode. Electrode 
polarization does not affect bioimpedance measurements,12 
and transmission of the current from the electrode to the 
hardware is performed by chronoamperometry.13
EIS and electrical conductivity
With direct current, the plasma membrane acts as an insu-
lator and the current is not able to penetrate the cell, so 
most of the current flows around the cell and therefore in 
the interstitial fluid.5 Analysis of the direct current at the 
cathode and anode in electrolytic solution is performed at Psychology Research and Behavior Management 2011:4 submit your manuscript | www.dovepress.com
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both the anode and the cathode. The electrical conductivity 
is measured in µSiemens. In this study, we considered only 
the pathway between the two disposable frontal electrodes 
(Ag/Ag/Cl). The electrochemical reaction at the cathode12 is: 
2H2O + 2e- = H2(gas) + 2OH-(base) and at the anode12 is:   
2H2O = O2(gas) + 4H+ + 4e-(acid).
EIS and electrical dispersion
The cell membrane has the ability to store capacitive energy 
via its dielectric or insulator properties. The cell membrane 
is the cellular structure that makes the major contribution to 
the dielectric behavior of living tissue. Living tissue is con-
sidered as a dispersive medium.13,14 Electrical dispersion is 
expressed by the α parameter value. In 1940, Cole introduced 
the first mathematical expression to describe the “depressed 
semicircles” found experimentally. This is known as the Cole 
equation, as follows:
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where Z is the impedance value at frequency ω, j is the 
complex number (-1)1/2, R∞ is the impedance at infinite 
frequency, R0 is the impedance at zero frequency, τ is the 
characteristic time constant, and α is a dimensionless param-
eter with a value between 0 and 1.13,14
Parameters analyzed
Statistical analysis was conducted to test for concordance 
between the bioimpedance measurements (electrical 
conductivity and electrical dispersion α parameter) and 
treatment responses according to Ham-D and CGI scores. 
A receiver-operating characteristic curve was constructed 
for bioimpedance measurements in the pathway of the fore-
head electrodes for Groups 1 and 2 at day 45, and another 
receiver-operating characteristic curve was constructed for 
bioimpedance measurements in the pathway of the forehead 
electrodes for Groups 3 and 4 at day 60.
Statistical analysis
Statistical analysis was performed using MedCalc software. 
The number of patients needed for the study was calculated 
to be 50 on the basis of α = 5%, at 80% power = F (∆, N, 
variability DS), taking into account the judgment criteria ∆ 
at approximately 50 DS (5% error). A P value of ,0.005 
was accepted as being statistically significant.
Results
Fifty-nine subjects were enrolled in the study and started on 
SSRI treatment of fluoxetine 20 mg/day.
At day 15, there were no responders to treatment, at 
day 30 there were six responders, at day 45 there were 34 
responders (Group 1) and 25 nonresponders (Group 2), at 
day 60, there were 38 responders (Group 3) and 21 nonre-
sponders (Group 4).
Electrical conductivity and electrical dispersion increased 
in the four groups during SSRI treatment. Demographic 
Table 1 Patient demographic data
Group 1 Group 2 Group 3 Group 4 P value
n 34 25 38 21
Age 47.1 46.8 47.8 46.3 NS
Male/female  
ratio
0.54 0.48 0.55 0.46 0.01
Conductivity 4.92 3.1 6.12 3.95 0.001
Dispersion 0.689 0.645 0.697 0.651 0.001
Ham-D ,50% .50% ,50% .50%
CGI average 1.75 3 1.60 3
Abbreviations: CGI, Clinical Global Impression scale; Ham-D, Hamilton Depression 
scale; NS, not significant.
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Figure 1 Comparing Group 1 (D+45 responders) and Group 2 (D+45 nonresponders), electrical conductivity measurement of the pathway between the two forehead 
electrodes.
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characteristics are shown in Table 1. Treatment responses 
were coded as 1 (response) and 0 (no response). Comparing 
Group 1 and Group 2, electrical conductivity measurement 
of the pathway between the two forehead electrodes had a 
specificity of 72% and sensitivity of 85.3% (P , 0.0001) 
with a cutoff .4.32 (see Figure 1). Comparing Group 3 and 
Group 4, the electrical conductivity of the same pathway had 
a specificity of 47.6% and a sensitivity of 76.3% (P , 0.16) 
with a cutoff .5.92 (see Figure 2). Comparing Group 1 and 
Group 2, electrical dispersion of the pathway between the two 
forehead electrodes had a specificity of 80% and a sensitiv-
ity of 85.2% (P , 0.0001) with a cutoff .0.678 (Figure 3). 
Comparing Group 3 and Group 4, electrical dispersion of the 
same pathway had a specificity of 100% and a sensitivity of 
89.5% (P , 0.0001) with a cutoff .0.692 (Figure 4).
Discussion
People respond differently to antidepressant treatment. With 
some knowledge of the therapeutic modalities available, 
both pharmacologic and nonpharmacologic, coupled with 
a reasonable amount of patience on the part of both the 
health care provider and the patient, treatment can be highly 
successful in regaining an appropriate level of well-being.16 
The antidepressant properties of SSRIs are due to increased 
concentrations of serotonin at the synaptic cleft, enhancing 
serotonergic transmission and inducing downregulation of 
postsynaptic receptors. Although neurotransmitter reuptake 
inhibition is an important property of SSRIs, the temporal 
difference between the rapid onset of this pharmacological 
effect and slower symptomatic relief suggests that second-
ary adaptive responses may contribute to the effectiveness 
of SSRIs as antidepressants.17 
Electroencephalography using disposable frontal elec-
trodes has been investigated in the prediction of response 
to antidepressant therapy. Various electroencephalographic 
parameters have been associated with response to treatment.18 
To our knowledge, this is the first study using the bioimped-
ance measurement with two components, ie, conductivity 
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Figure 2 Comparing Group 3 (D+60 responders) and Group 4 (D+60 non responders), electrical conductivity measurement of the pathway between the two forehead 
electrodes.
Note: aBinomial exact.
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Figure 3 Comparing Group 1 (D+45 responders) and Group 2 (D+45 nonresponders), electrical dispersion of the pathway between the two forehead electrodes
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and dispersion, to monitor response to an antidepressant 
therapy. In our study, the best indicator of treatment response 
was the dispersion α parameter at day 60, with a specific-
ity of 100%, a sensitivity of 89.5% (P , 0.0001), and a   
cutoff .0.692.
Ivorra et al16 investigated the significance of the disper-
sion α parameter by computer simulations and demonstrated 
its practical importance in a rat kidney model. The simula-
tions indicated that the dispersion width is determined by 
the morphology of the extracellular space and suggest that 
this technique could detect structural tissue changes. One 
explanation as to why electrical conductivity measurements 
increased in the forehead pathway after 45 days of SSRI 
treatment could be related to an increased concentration of 
serotonin at the synaptic cleft and an associated change in 
cerebral tissue blood flow. A second explanation as why the 
dispersion α parameter increased in the forehead pathway 
after 45 and 60 days of SSRI treatment could be related to 
changes in the morphology of the extracellular space in the 
cerebral tissue.
Conclusion
EIS electrical conductivity measurement in the forehead 
pathway showed high specificity and sensitivity at day 45 
for distinguishing between responders and nonresponders 
to SSRI therapy. The specificity and sensitivity decreased 
at day 60. The EIS electrical dispersion α parameter in the 
forehead pathway has a high specificity and sensitivity at day 
45 when comparing responders and nonresponders, and the 
specificity and sensitivity increase at day 60. EIS could be a 
low-cost noninvasive system that is easy to use in the office 
and may become an adjunct to DSM-IV questionnaires and 
Clinical Global Impression scores for monitoring the efficacy 
of treatment for major depressive disorder. Longitudinal 
studies are now under way to confirm our findings.
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